Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2021.1884677
Abstract: ABSTRACT Introduction Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive… read more here.
Keywords: relapsed refractory; treatment; tafasitamab; diffuse large ... See more keywords
Abstract CT022: Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the phase II L-MIND study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct022
Abstract: Background: Tafasitamab, an anti-CD19 immunotherapy that enhances antibody-dependent cellular cytotoxicity and phagocytosis, received accelerated approval in the USA and conditional authorization in Europe in combination with lenalidomide (LEN) for patients (pts) with relapsed or refractory… read more here.
Keywords: year; relapsed refractory; efficacy; tafasitamab ... See more keywords